FEATURED APPLICATION CONTENT

• Optimization And Scale-Up Of A Plasmid DNA Production Process

  Optimizing pDNA production in E. coli requires strategic media selection and scale-up planning. Explore a study that identifies ideal conditions for high-yield manufacturing.

• Overcoming Unique Client Challenges With A Strong Collaborative Partnership

  Through close collaboration, proactive communication, and agile project management, our partnership accelerated an oncology program and helped overcome complex preclinical hurdles.

• BxPC-3: Evaluating Responses To Standard Therapeutic Agents

  Review multiple studies utilizing the BxPC-3 human pancreatic cancer model in subcutaneous (SC) NSG and NSG-dKO mouse models, evaluating a range of standard agents, vehicles, and delivery methods.

• A Risk-Based Approach To Plasmid DNA And mRNA Process Development

  Balancing robust analytics and clinical readiness is key for early-phase pDNA and mRNA therapeutics amid structural complexity and regulatory challenges.

• Preclinical Technique To Assess Targeted Therapies For Primary, Metastatic NSCLC

  To enable comprehensive evaluation of therapies targeting both primary and metastatic tumors, we've developed dual-disease xenograft models using bioluminescence imaging (BLI).

• Characterize Your PROTAC Hook Effect With Flexible In-Solution Affinity Measurements

  Characterizing the PROTAC hook effect is crucial for selecting candidates with enhanced cooperativity. Gain confidence with flexible, in-solution affinity measurements that reveal key biophysical parameters and align with established three-component binding models.

• Aggregation In Antibody-Drug Conjugates: Causes And Mitigation

  Discover how early intervention in ADC development can streamline clinical progress, ensure stability and safety, and accelerate commercialization with expert guidance.

• Time To Intensify: Taking mAb Manufacturing To The Next Level

  Explore how process intensification can revolutionize monoclonal antibody manufacturing to boost productivity, cut costs, and enhance sustainability with scalable strategies and real-world results.

• Cell Line Development For Bispecific Antibodies

  See how the recently described cell line development paradigm shift, enabled by the Leap-In transposon platform, can extend to the development of bispecific monoclonal antibody-producing cell substrates.

• Zero To Final Fill: How HUGEL Implemented Its First Single-Use Lines

  As regulations tighten, biomanufacturers are adopting single-use tech to boost compliance, reduce labor, and streamline fill-finish operations from the ground up.

• Optimizing CHO Cell Culture Using A Design Of Experiments Approach

  Learn how researchers optimized CHO cell culture to boost IgG1 titer to 5.8 g/L and improve viability, which cut development time from 14 days to 12 while enhancing productivity.

• Pre-Clinical Risk Assessment Of PCSK9 Guide RNAs

  Learn how a comprehensive, variant-aware screening workflow for therapeutic gene editing can identify and nominate the most favorable guide RNAs for clinical development.